Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
11.45
-0.63 (-5.22%)
At close: Jul 10, 2026, 4:00 PM EDT
11.70
+0.25 (2.18%)
After-hours: Jul 10, 2026, 6:26 PM EDT
Kura Oncology Revenue
Kura Oncology had revenue of $18.27M in the quarter ending March 31, 2026, with 29.47% growth. This brings the company's revenue in the last twelve months to $71.64M, up 5.37% year-over-year. In the year 2025, Kura Oncology had annual revenue of $67.48M with 25.24% growth.
Revenue (ttm)
$71.64M
Revenue Growth
+5.37%
P/S Ratio
14.19
Revenue / Employee
$275,535
Employees
260
Market Cap
1.02B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.48M | 13.60M | 25.24% |
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 369.49M |
| Phathom Pharmaceuticals | 204.89M |
| Lexicon Pharmaceuticals | 69.64M |
| Janux Therapeutics | 13.73M |
| Inventiva | 7.94M |
| DBV Technologies | 5.74M |
| Avalo Therapeutics | 59.00K |
KURA News
- 8 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Kura Oncology Transcript: Status update - Transcripts
- 4 weeks ago - Kura Oncology Press release: Status update - Filings
- 4 weeks ago - Kura Oncology Slides: Status update - Filings
- 4 weeks ago - Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML - GlobeNewsWire
- 5 weeks ago - Kura Oncology Transcript: Investor update - Transcripts
- 5 weeks ago - Kura Oncology Press release: Investor update - Filings
- 5 weeks ago - Kura Oncology Slides: Investor update - Filings